Human Risks from the Combustion of SRM-Derived Tallow in Ireland

The identification of meat and bone meal (MBM) as a significant factor in the spread of bovine spongiform encephalopathy (BSE) has resulted in the introduction of restrictions on the use and movement of MBM and tallow. This has led to a requirement for alternative uses for these products. This paper reports on a risk assessment performed on the use of tallow as a fuel oil extender in diesel engines. With up to 4000 tonnes of tallow being produced each year in Ireland, combustion with energy recovery represents a viable, cost-efficient utilization route. A stochastic (Latin Hypercube sampling) simulation model was developed to assess the infectiv-ity risk to humans associated with potential airborne exposure to the combustion products when using tallow as a combustion fuel in diesel engines. The model simulates the potential infectivity pathways that tallow follows, including its production from animals with potentially subclinical BSE and processing the tallow with segregation and heat treatments. The model uses probability distributions for the most important input parameters. The assessment takes into account a number of epidemiological parameters that include tissue infectivity, species barrier, disease incidence, and heat inactivation. Two scenarios, reflecting the infectivity risk in different animal tissues defined by the European Commissions Scientific Steering Committee (SSC), were performed. It is seen from the model results that the risk of a human contracting variant Creutzfeldt-Jakob Disease (vCJD) from potential airborne exposure to BSE, resulting from the combustion of tallow, is extremely small even when model uncertainty is taken into account (mean individual risk values ranging from 10^-11.43 to 10^-7.23 per year/person). The risks are a number of orders of magnitude less than the sporadic annual incidence level of Creutzfeldt-Jakob Disease 9CJD) in Europe (approximately 10^-6)     

Feasibility of allogeneic mesenchymal stem cells in pediatric hypoxic-ischemic encephalopathy: Phase I study

BACKGROUNDHypoxic-ischemic encephalopathy (HIE) is one of the leading causes of death and long-term neurological impairment in the pediatric population. Despite a limited number of treatments to cure HIE, stem cell therapies appear to be a potential treatment option for brain injury resulting from HIE.AIMTo investigate the efficacy and safety of stem cell-based therapies in pediatric patients with HIE.METHODSThe study inclusion criteria were determined as the presence of substantial deficit and disability caused by HIE. Wharton’s jelly-derived mesenchymal stem cells (WJ-MSCs) were intrathecally (IT), intramuscularly (IM), and intravenously administered to participants at a dose of 1 × 10⁶/kg for each administration route twice monthly for 2 mo. In different follow-up durations, the effect of WJ-MSCs administration on HIE, the quality of life, prognosis of patients, and side effects were investigated, and patients were evaluated for neurological, cognitive functions, and spasticity using the Wee Functional Independence Measure (Wee FIM) Scale and Modified Ashworth (MA) Scale. RESULTSFor all participants (n = 6), the mean duration of exposure to hypoxia was 39.17 + 18.82 min, the mean time interval after HIE was 21.83 ± 26.60 mo, the mean baseline Wee FIM scale score was 13.5 ± 0.55, and the mean baseline MA scale score was 35 ± 9.08. Three patients developed only early complications such as low-grade fever, mild headache associated with IT injection, and muscle pain associated with IM injection, all of which were transient and disappeared within 24 h. The treatment was evaluated to be safe and effective as demonstrated by magnetic resonance imaging examinations, electroencephalographies, laboratory tests, and neurological and functional scores of patients. Patients exhibited significant improvements in all neurological functions through a 12-mo follow-up. The mean Wee FIM scale score of participants increased from 13.5 ± 0.55 to 15.17 ± 1.6 points (mean ± SD) at 1 mo (z = - 1.826, P = 0.068) and to 23.5 ± 3.39 points at 12 mo (z = -2.207, P = 0.027) post-treatment. The percentage of patients who achieved an excellent functional improvement (Wee FIM scale total score = 126) increased from 10.71% (at baseline) to 12.03% at 1 mo and to 18.65% at 12 mo post-treatment. CONCLUSIONBoth the triple-route and multiple WJ-MSC implantations were safe and effective in pediatric patients with HIE with significant neurological and functional improvements. The results of this study support conducting further randomized, placebo-controlled studies on this treatment in the pediatric population.